Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of YLSH003 in advanced solid tumors
CTR20254028Phase 2Active
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YLSH003 in Nonhematologic neoplasms, sponsored by Chengdu Easton Biopharmaceuticals Co., Ltd. Primary endpoints: Phase I dose-limiting toxicity and safety and Phase II objective response rate. Started Nov 2025; status: active.
02
Drugs
YLSH003
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254028.